摘要
目的研究CCR7在NSCLC中的表达情况,探讨其与NSCLC的临床病理关系。方法采取链霉素抗生物素蛋白-过氧化物酶免疫组化法检测36例非小细胞肺癌组织、5例正常肺组织CCR7的表达情况及肺癌组织D2-40的表达情况。结果CCR7主要表达在细胞膜及细胞质,36例组织标本中29例阳性表达,阳性率为80.56%;正常肺组织的阳性率为10.00%。癌组织淋巴结阳性标本中CCR7阳性率为84.21%,阴性标本阳性率为52.94%(P<0.05)。结论 CCR7在肺癌组织中高表达,并随着TNM分期的提高,CCR7的表达也逐渐提高。并且CCR7高表达的癌组织样本中D2-40也呈现高表达。NSCLC淋巴结转移与癌组织中的CC7高表达关联密切,可能为今后预测NSCLC患者预后及治疗提供有力的理论依据。
Objective To investigate the expression of CCR7 in NSCLC and to explore its clinicopathological relationship with NSCLC. Methods The expression of CCR7 in 36 cases of non-small cell lung cancer tissues and 5 normal lung tissues and the expression of D2-40 in lung cancer tissues were detected by streptomycin avidin-peroxidase immunohistochemistry.Results CCR7 was mainly expressed in cell membrane and cytoplasm,and 29 cases were positively expressed in 36 tissue samples,the positive rate was 80.56%; the positive rate of normal lung tissue was 10.00%.The positive rate of CCR7 in cancer tissue-positive specimens was 84.21%,and the positive rate in negative specimens was 52.94%（P〈0.05）.Conclusion CCR7 is highly expressed in lung cancer tissues,and the expression of CCR7 is gradually increased with the increase of TNM staging.And D2-40 also showed high expression in cancer tissue samples with high CCR7 expression.NSCLC lymph node metastasis is closely related to the high expression of CC7 in cancer tissues, which may provide a powerful theoretical basis for predicting the prognosis and treatment of patients with NSCLC.
作者
李春磊
裴艳志
邹志田
高磊
路通
凡航
朱晓峰
LI Chun-lei;PEl Yan-zhi;ZOU Zhi-tian;GAO Lei;LU Tong;FAN Hang;ZHU Xiao-feng(Department of Thoracic Surgery,the First Affiliated Hospital of Jiamusi University,Jiamusi 154000,Heilongjiang,China)
出处
《医学信息》
2018年第17期14-16,共3页
Journal of Medical Information
关键词
非小细胞肺癌
CCR7
淋巴结转移
Non-small cell lung cancer
CCR7
Lymph node metastasis
